Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Noberasco
Cristina
C
De Pas
Tommaso
T
Curigliano
Giuseppe
G
Manzoni
Sara
S
Dodaro
Lucia
L
Pelosi
Giuseppe
G
Spaggiari
Lorenzo
L
De Braud
Filippo
F
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000188:drug therapy*; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077156:Gefitinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases